Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)

Publication | Closed Access

DOI

Citations

References

2022

Year

Ning Li, Jianqing Zhu, Rutie Yin, Jing Wang, Lingya Pan, Beihua Kong, Hong Zheng, Jihong Liu, Xiaohua Wu, Li Wang,

Gynecologic Oncology

Prime StudyMaintenance TreatmentMedicineCancer ManagementGynecologyPharmacotherapyCancer TreatmentOncologyIndividualized Starting DoseGynecology OncologyOvarian Cancer